Immunocompromised and other high-risk patients with suspected infections typically receive empiric broad spectrum antimicrobial therapy due to the inability to identify a specific pathogen in clinical samples obtained from patients who present with fever and other signs of infection.
- Limitations with current testing methodologies (e.g. blood cultures and PCR) result in the failure to identify the causative pathogen in 60% to 85% of high risk patients.
- This leads to the inability to target therapies to specific pathogens and contributes to:
– ineffective treatments
– the overuse of broad spectrum antibiotice
– an increased risk of developing bacterial and fungal overgrowth infections
– the emergence of antibiotic resistance
– higher costs of medical care
PathoQuest’s NGS pathogen identification testing approach uses a process called metagenomics to provide a more sensitive and comprehensive approach to the identification of pathogens enabling targeted antimicrobial therapy and improved antibiotic stewardship.
PathoQuest’s patented, game-changing metagenomics approach to pathogen identification permits the identification of pathogens from blood samples via the following 3-step process:
Click here for more detailed information of PathoQuest’s NGS-based solution for identifying clinical pathogens.